Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

Table 4 Estimation of MCID estimates in mRSS using HAQ-DI anchor for all participants

HAQ-DI	N	Unadjusted mean			Effect size
HAQ-DI	N	Mean	95% LCL	95% UCL	Effect size
Overall
Change ≤ − 0.48	38	− 6.11	− 8.29	− 3.92	− 0.57
− 0.14 ≥ change > − 0.48 (MCID estimate for improvement)	34	− 3.56	− 6	− 1.12	− 0.33
− 0.14 < change < 0.14	108	− 2.55	− 3.47	− 1.62	− 0.24
0.14 ≤ change < 0.48	26	− 0.88	− 2.84	1.07	− 0.08
Change ≥ 0.48	37	− 1.03	− 3.14	1.09	− 0.10
Diffuse SSc
Change ≤ − 0.48	29	− 7.97	− 10.41	− 5.52	− 0.83
− 0.14 ≥ change > − 0.48 (MCID estimate for improvement)	22	− 4.64	− 8.28	− 0.99	− 0.48
− 0.14 < change < 0.14	54	− 4.8	− 6.23	− 3.36	− 0.50
0.14 ≤ change < 0.48	16	− 1.69	− 4.88	1.5	− 0.18
Change ≥ 0.48	25	− 1.48	− 4.56	1.6	− 0.15
Limited SSc
Change ≤ − 0.48	9	− 0.11	− 2.3	2.08	− 0.03
− 0.14 ≥ change > − 0.48 (MCID estimate for improvement)	12	− 1.58	− 3.74	0.57	− 0.44
− 0.14 < change < 0.14	54	− 0.3	− 1.15	0.56	− 0.08
0.14 ≤ change < 0.48	10	0.4	− 0.68	1.48	0.11
Change ≥ 0.48	12	− 0.08	− 1.99	1.82	− 0.02

HAQ-DI Health Assessment Questionnaire -Disability Index, LCL lower confidence limit, MCID minimal clinically important difference, mRSS modified Rodnan Skin Score, SSc systemic sclerosis, UCL upper confidence limit

ISSN: 1478-6362